ONPH (Oncology Pharma) ROC %: -141.48% (As of Dec. 2004)

What is Oncology Pharma ROC %?

Oncology Pharma ONPH +15.99% ROC % is -141.48% as of Dec. 2004.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Oncology Pharma's annualized return on capital (ROC %) for the quarter that ended in Dec. 2004 was -141.48%.

As of today (2026-06-26), Oncology Pharma's WACC % is 0.00%. Oncology Pharma's ROC % is 0.00% (calculated using TTM income statement data). Oncology Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Oncology Pharma (OTCPK:ONPH) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Oncology Pharma's WACC % is 0.00%. Oncology Pharma's ROC % is 0.00% (calculated using TTM income statement data). Oncology Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Oncology Pharma ROC % Related Terms

Oncology Pharma ROC % Historical Data

* Premium members only.

The historical data trend for Oncology Pharma's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncology Pharma ROC % Chart

Oncology Pharma Annual Data

Trend

Jun96

Jun97

Jun98

Mar00

Mar01

Mar02

Mar03

ROC %

Get a 7-Day Free Trial

-785.15

-880.33

-204.18

-245.40

-279.69

Oncology Pharma Quarterly Data
	Mar00	Jun00	Sep00	Dec00	Mar01	Jun01	Sep01	Dec01	Mar02	Jun02	Sep02	Dec02	Mar03	Jun03	Sep03	Dec03	Mar04	Jun04	Sep04	Dec04
ROC %	Get a 7-Day Free Trial															-1,147.83	-1,939.87	-489.12	-35.71	-141.48

Oncology Pharma ROC % Calculation

Oncology Pharma's annualized Return on Capital (ROC %) for the fiscal year that ended in Mar. 2003 is calculated as:

	ROC % (A: Mar. 2003 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Mar. 2002 )	+	Invested Capital (A: Mar. 2003 ))	/ count )
=	-1.625 * ( 1 - 0% )	/	( (0.841	+	0.321)	/ 2 )
=	-1.625	/	0.581
=	-279.69 %

where

	Invested Capital		(A: Mar. 2002 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.611	-	0.909	-	( 2.934	-	max(0, 1.239	-	3.1	+	2.934	))
=	0.841

	Invested Capital		(A: Mar. 2003 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.751	-	0.733	-	( 1.346	-	max(0, 0.879	-	1.576	+	1.346	))
=	0.321

Oncology Pharma's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2004 is calculated as:

	ROC % (Q: Dec. 2004 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2004 )	+	Invested Capital (Q: Dec. 2004 ))	/ count )
=	-0.324 * ( 1 - 0% )	/	( (0.168	+	0.29)	/ 2 )
=	-0.324	/	0.229
=	-141.48 %

where

	Invested Capital		(Q: Sep. 2004 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.002	-	0.199	-	( 0.002	-	max(0, 0.367	-	0.002	+	0.002	))
=	0.168

	Invested Capital		(Q: Dec. 2004 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.043	-	0.199	-	( 0.043	-	max(0, 0.489	-	0.043	+	0.043	))
=	0.29

Note: The Operating Income data used here is four times the quarterly (Dec. 2004) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -141.48% mean?

Oncology Pharma (ONPH) has a ROC % of -141.48% as of Dec. 2004. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Oncology Pharma and its competitors.

Is Oncology Pharma's ROC % too high?

Oncology Pharma's current ROC % is -141.48%.

How does Oncology Pharma's ROC % compare to TAUG and IMUN?

Oncology Pharma's ROC % of -141.48% can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Diversified Financial Services company?

A good ROC % depends on the Diversified Financial Services industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Oncology Pharma and its competitors. Oncology Pharma's current ROC % is -141.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Oncology Pharma stock overvalued right now?

Oncology Pharma (ONPH) has a current ROC % of -141.48%. The current ROC % is -141.48%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Oncology Pharma (ONPH), the current ROC % is -141.48% as of Dec. 2004. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oncology Pharma Business Description

Industry Financial Services Diversified Financial Services

Comparable Companies XSAT:CLINE B ASX:ATX TAUG IMUN WAR:RDG TSXV:NLTA TNTY USRM TSXV:IBT LSE:PYC TSXV:THRM SGBI BZYR XSAT:EUCI OSL:ABT RTTR TNXP TSXV:VXL BOM:526139 WIZP

Address 732 S 6TH Street, Suite R, Las Vegas, NV, USA, 89101

Website https://www.oncology-pharma.com

Oncology Pharma Inc is a shell company and currently has no operations.